Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-particles for targeted therapy.

George Sgouros1

  • 1Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore MD USA. gsgouro1@jhmi.edu

Advanced Drug Delivery Reviews
|June 11, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457.

International journal of radiation oncology, biology, physics·2026
Same author

Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging.

Scientific reports·2025
Same author

MRI detects tubulointerstitial changes in mouse models of radiation-induced nephropathy.

Magnetic resonance in medicine·2025
Same author

Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.

International journal of radiation oncology, biology, physics·2025
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Alpha-particles, helium nuclei, deliver potent DNA damage for targeted therapy. Their irreparable damage offers a novel approach, showing efficacy with minimal toxicity in early trials.

Area of Science:

  • Nuclear Physics and Radiation Biology
  • Oncology
  • Radiochemistry

Background:

  • Alpha-particles (helium nuclei) deposit significantly more DNA-damaging energy than beta-particles.
  • Alpha-particle radiation causes irreparable double-stranded DNA breaks, leading to cell sterilization.
  • This mechanism bypasses resistance often seen with conventional radiotherapy, particularly in hypoxic tissues.

Purpose of the Study:

  • To investigate alpha-particle emitting radionuclides for targeted cancer therapy.
  • To evaluate the efficacy and toxicity of alpha-particle targeted therapy.
  • To highlight the unique radiobiological properties of alpha-particles.

Main Methods:

  • Review of preclinical (animal and cell culture) studies on alpha-particle effects.

Related Experiment Videos

  • Analysis of data from early-phase clinical trials of alpha-particle targeted therapy.
  • Comparison of biological effects per unit absorbed dose with beta-particle and external beam radiation.

    • Main Results:

    • Alpha-particles are 100-1000 times more energetic than beta-particles, causing severe, irreparable DNA damage.
    • Per unit absorbed dose, alpha-particles exhibit 3-7 times greater acute biological effects than external beam or beta-particle radiation.
    • Clinical trials indicate efficacy and minimal toxicity for alpha-particle targeted therapy.

    Conclusions:

    • Alpha-particle emitting radionuclides represent a promising new class for targeted therapy.
    • The potent and irreparable DNA damage mechanism offers advantages over conventional radiotherapy.
    • Early clinical results support the therapeutic potential of alpha-particles with a favorable safety profile.